Which has preferable earnings & valuation, INMD or LUCD?

InMode has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.30 $93.83M $1.36 10.88 Lucid Diagnostics $4.71M 46.13 -$58.01M -$0.47 N/A

Is INMD or LUCD more profitable?

InMode has a net margin of 23.27% compared to Lucid Diagnostics' net margin of -876.72%. InMode's return on equity of 13.47% beat Lucid Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% Lucid Diagnostics -876.72% N/A -116.26%

Does the media favor INMD or LUCD?

In the previous week, InMode had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 5 mentions for InMode and 3 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.00 beat InMode's score of -0.33 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LUCD or BVS?

In the previous week, Lucid Diagnostics had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Lucid Diagnostics and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.33 beat Lucid Diagnostics' score of 0.00 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, LUCD or SIBN?

SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lucid Diagnostics $4.71M 46.13 -$58.01M -$0.47 N/A SiBone $206.22M 3.68 -$18.90M -$0.39 N/A

Is LUCD or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% SiBone -8.10% -9.56% -7.06%

Does the media favor CBLL or LUCD?

In the previous week, CeriBell had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 7 mentions for CeriBell and 3 mentions for Lucid Diagnostics. CeriBell's average media sentiment score of 0.10 beat Lucid Diagnostics' score of 0.00 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SSII or LUCD?

In the previous week, SS Innovations International had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for SS Innovations International and 3 mentions for Lucid Diagnostics. SS Innovations International's average media sentiment score of 0.72 beat Lucid Diagnostics' score of 0.00 indicating that SS Innovations International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lucid Diagnostics (LUCD) Competitors

$1.07 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.07 +0.00 (+0.37%)

As of 07/2/2026 07:40 PM Eastern

Compare

LUCD vs. INMD, BVS, SIBN, CBLL, and SSII

Should you buy Lucid Diagnostics stock or one of its competitors? MarketBeat compares Lucid Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lucid Diagnostics include InMode (INMD), Bioventus (BVS), SiBone (SIBN), CeriBell (CBLL), and SS Innovations International (SSII). These companies are all part of the "medical equipment" industry.

How does Lucid Diagnostics compare to InMode?

InMode (NASDAQ:INMD) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

InMode has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

InMode has a net margin of 23.27% compared to Lucid Diagnostics' net margin of -876.72%. InMode's return on equity of 13.47% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Lucid Diagnostics	-876.72%	N/A	-116.26%

In the previous week, InMode had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 5 mentions for InMode and 3 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.00 beat InMode's score of -0.33 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMode presently has a consensus price target of $16.00, indicating a potential upside of 8.11%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 291.36%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

InMode has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.30	$93.83M	$1.36	10.88
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A

68.0% of InMode shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

InMode beats Lucid Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Bioventus?

Lucid Diagnostics (NASDAQ:LUCD) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Bioventus has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56

Lucid Diagnostics presently has a consensus price target of $4.19, suggesting a potential upside of 291.36%. Bioventus has a consensus price target of $14.20, suggesting a potential upside of 35.50%. Given Lucid Diagnostics' higher probable upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has a net margin of 4.94% compared to Lucid Diagnostics' net margin of -876.72%. Bioventus' return on equity of 29.97% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Bioventus	4.94%	29.97%	9.52%

In the previous week, Lucid Diagnostics had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Lucid Diagnostics and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.33 beat Lucid Diagnostics' score of 0.00 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lucid Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Summary

Bioventus beats Lucid Diagnostics on 11 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to SiBone?

Lucid Diagnostics (NASDAQ:LUCD) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A
SiBone	$206.22M	3.68	-$18.90M	-$0.39	N/A

In the previous week, Lucid Diagnostics had 3 more articles in the media than SiBone. MarketBeat recorded 3 mentions for Lucid Diagnostics and 0 mentions for SiBone. Lucid Diagnostics' average media sentiment score of 0.00 equaled SiBone'saverage media sentiment score.

Company	Overall Sentiment
Lucid Diagnostics	Neutral
SiBone	Neutral

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
SiBone	-8.10%	-9.56%	-7.06%

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lucid Diagnostics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Lucid Diagnostics currently has a consensus target price of $4.19, suggesting a potential upside of 291.36%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 34.42%. Given Lucid Diagnostics' higher possible upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats Lucid Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

CeriBell currently has a consensus price target of $22.20, suggesting a potential upside of 13.55%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 291.36%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, CeriBell had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 7 mentions for CeriBell and 3 mentions for Lucid Diagnostics. CeriBell's average media sentiment score of 0.10 beat Lucid Diagnostics' score of 0.00 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell has a net margin of -63.51% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Lucid Diagnostics	-876.72%	N/A	-116.26%

CeriBell has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

CeriBell has higher revenue and earnings than Lucid Diagnostics. CeriBell is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.80	-$53.41M	-$1.63	N/A
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A

74.0% of Lucid Diagnostics shares are owned by institutional investors. 20.1% of CeriBell shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CeriBell beats Lucid Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

SS Innovations International has a beta of -1.96, indicating that its stock price is 296% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, SS Innovations International had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for SS Innovations International and 3 mentions for Lucid Diagnostics. SS Innovations International's average media sentiment score of 0.72 beat Lucid Diagnostics' score of 0.00 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SS Innovations International has a net margin of -20.69% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Lucid Diagnostics	-876.72%	N/A	-116.26%

SS Innovations International has higher revenue and earnings than Lucid Diagnostics. SS Innovations International is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	17.80	-$12.13M	-$0.05	N/A
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A

SS Innovations International presently has a consensus target price of $7.00, suggesting a potential upside of 85.19%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 291.36%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

74.0% of Lucid Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lucid Diagnostics beats SS Innovations International on 9 of the 16 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$217.28M	$7.57B	$7.16B	$12.48B
Dividend Yield	N/A	1.32%	2.66%	6.52%
P/E Ratio	-2.28	52.12	28.02	24.70
Price / Sales	46.13	49.46	540.37	99.49
Price / Cash	N/A	26.72	49.26	57.09
Price / Book	-3.45	7.48	10.96	6.46
Net Income	-$58.01M	$159.19M	$3.57B	$337.01M
7 Day Performance	-0.93%	-0.39%	2.12%	1.69%
1 Month Performance	10.63%	-0.43%	5.25%	3.81%
1 Year Performance	-1.47%	3.14%	33.29%	23.90%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	3.4493 of 5 stars	$1.07 flat	$4.19 +291.4%	-1.5%	$217.28M	$4.71M	N/A	70	News Coverage Analyst Downgrade
INMD InMode	1.3103 of 5 stars	$13.35 +1.1%	$16.00 +19.9%	-2.3%	$759.32M	$370.49M	9.82	480	News Coverage
BVS Bioventus	4.1166 of 5 stars	$9.29 +5.7%	$14.20 +52.9%	N/A	$734.27M	$568.09M	22.66	1,200	News Coverage Analyst Forecast
SIBN SiBone	1.8181 of 5 stars	$15.95 +0.8%	$23.00 +44.2%	-7.3%	$701.61M	$200.93M	N/A	350
CBLL CeriBell	1.7202 of 5 stars	$18.39 +1.2%	$22.20 +20.7%	+3.3%	$689.80M	$89.06M	N/A	N/A	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. INMD, BVS, SIBN, CBLL, and SSII

How does Lucid Diagnostics compare to InMode?

Summary

How does Lucid Diagnostics compare to Bioventus?

Summary

How does Lucid Diagnostics compare to SiBone?

Summary

How does Lucid Diagnostics compare to CeriBell?

Summary

How does Lucid Diagnostics compare to SS Innovations International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. INMD, BVS, SIBN, CBLL, and SSII

How does Lucid Diagnostics compare to InMode?

Which has more risk & volatility, INMD or LUCD?

Is INMD or LUCD more profitable?

Does the media favor INMD or LUCD?

Do analysts prefer INMD or LUCD?

Which has preferable earnings & valuation, INMD or LUCD?

Do institutionals & insiders have more ownership in INMD or LUCD?

Summary

How does Lucid Diagnostics compare to Bioventus?

Which has higher valuation and earnings, LUCD or BVS?

Do analysts rate LUCD or BVS?

Is LUCD or BVS more profitable?

Does the media prefer LUCD or BVS?

Do insiders and institutionals hold more shares of LUCD or BVS?

Which has more risk and volatility, LUCD or BVS?

Summary

How does Lucid Diagnostics compare to SiBone?

Which has stronger earnings & valuation, LUCD or SIBN?

Does the media prefer LUCD or SIBN?

Is LUCD or SIBN more profitable?

Do insiders & institutionals hold more shares of LUCD or SIBN?

Which has more volatility and risk, LUCD or SIBN?

Do analysts rate LUCD or SIBN?

Summary

How does Lucid Diagnostics compare to CeriBell?

Do analysts recommend CBLL or LUCD?

Does the media favor CBLL or LUCD?

Is CBLL or LUCD more profitable?

Which has more risk and volatility, CBLL or LUCD?

Which has higher earnings & valuation, CBLL or LUCD?

Do institutionals and insiders hold more shares of CBLL or LUCD?

Summary

How does Lucid Diagnostics compare to SS Innovations International?

Which has more risk & volatility, SSII or LUCD?

Does the media favor SSII or LUCD?

Is SSII or LUCD more profitable?

Which has preferable valuation & earnings, SSII or LUCD?

Do analysts recommend SSII or LUCD?

Do institutionals & insiders hold more shares of SSII or LUCD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools